Drugs / LY5625573
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07867340 | Sep 2026 → Jan 2027 expected | — | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY5625573 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07867340 ↗ |
| Route | Oral | “Administered orally as tablet” NCT07867340 ↗ |